Date: Wednesday 28 Mar 2012
BioSeek, a subsidiary of drugs developer Asterand, has signed a new three-year collaboration agreement with Merck Serono, a division of German pharmaceuticals giant firm Merck. The new agreement is for a research plan which extends and expands the companies' previous three-year agreement from 2009. The studies carried out by BioSeek for Merck Serono over the past three years have demonstrated that the BioMAP platform can be used to reliably advance promising molecules through pre-clinical evaluation, the company claimed.
| Issue of Equity | 18-May-2012 | 17:26 | RNS |
| Holding(s) in Company | 03-May-2012 | 15:45 | RNS |
| Holding(s) in Company | 03-May-2012 | 15:45 | RNS |
| Change of Registered Office | 20-Apr-2012 | 13:03 | RNS |
| Folkestone Women's Health Project | 19-Apr-2012 | 07:00 | RNS |
No recent information was found.
| The Week Ahead: Pearson profits expected to hit ... | 26-Feb-2007 | The Independent |
No recent information was found.
| Yesterday's trading: Pru favourite to win United... | 07-Apr-2009 | This Is Money |
Shares in CareCapital Group PLC soa... |
06-Apr-2009 | Proactive Investors |
| Currency | UK Pounds |
| Share Price | 1.18p |
| Change Today | -0.050p |
| % Change | -4.08 % |
| 52 Week High | 3.25 |
| 52 Week Low | 1.15 |
| Volume | 65,000 |
| Shares Issued | 163.41m |
| Market Cap | £1.92m |
| Value | ![]() |
|---|
| Price Trend |
|
|---|
| Income | ![]() |
|---|
| Growth |
|
|---|
| No dividends found |
| Time | Volume / Share Price |
| 14:27 | 40,000 @ 1.18p |
| 09:02 | 25,000 @ 1.15p |
| Chair | Michael J Sinclair |
| CEO | Paul Stacey |
| Finance Director | Steve Wilden |
| Finance Director | Don Baladasan |
You are here: research